Role of Community Pharmacies for the Detection of Potentially Inappropriate Xanthine Oxidase Inhibitor Prescriptions.

Autor: Pasina L; Drug Information Service for the Elderly, Laboratory for Quality Assessment of Geriatric Therapies and Services, IRCCS-Istituto di Ricerche Farmacologiche 'Mario Negri', Via Giuseppe La Masa, 19, 20156, Milano, Italy. luca.pasina@marionegri.it., Urru SA; CRS4, Biomedicine Sector, Center for Advanced Studies, Research and Development in Sardinia Technology Park Polaris, Building 1 Piscina Manna, 09010, Pula, CA, Italy., Minghetti P; Department of Pharmaceutical Sciences, Università degli Studi di Milano, Milano, Italy., Giua C; Dipartimento Scienze della Vita, Università degli Studi di Trieste, Trieste, Italy.
Jazyk: angličtina
Zdroj: Drugs - real world outcomes [Drugs Real World Outcomes] 2015 Mar; Vol. 2 (1), pp. 81-86.
DOI: 10.1007/s40801-015-0016-7
Abstrakt: Background: Xanthine oxidase (XO) inhibitors are largely the treatment of choice for gout, but allopurinol is often inappropriately used for asymptomatic hyperuricemia. There is little evidence that allopurinol is useful in preventing cardiovascular diseases and therapeutic decisions must the balance the expected benefit with the potential harm.
Objective: To investigate the appropriateness of XO inhibitor use in relation to evidence-based indications and examine the role of community pharmacies in the detection of inappropriate prescriptions of these drugs.
Methods: This is an observational study conducted in eight community pharmacies. Each pharmacist was asked to interview a sample of patients who had received prescriptions of XO inhibitors. Patients were asked to complete a structured minimum data set that collected information on drug indication, history of gout, and presence of cardiovascular diseases.
Results: The study sample included 74 patients receiving XO inhibitors. About one third of patients reported being treated for asymptomatic hyperuricemia and had never had a gout attack. About half of the patients treated for asymptomatic hyperuricemia had been receiving the drug treatment for more than 3 years. Four asymptomatic hyperuricemic patients received allopurinol to treat hypertension. Among the patients treated for asymptomatic hyperuricemia, there was a higher presence of diabetes mellitus, obesity, previous myocardial infarction, and heart failure than in patients treated for an appropriate indication.
Conclusions: Inappropriate use of XO inhibitors is principally related to the treatment of hyperuricemia in patients with cardiovascular diseases. Community pharmacists have a central role in pharmacovigilance, by contributing to the prevention and identification of potentially inappropriate drug prescriptions.
Databáze: MEDLINE
Externí odkaz: